RFC
VNDA icon

Russell Frank Company’s Vanda Pharmaceuticals VNDA Stock Holding History

Russell Frank Company’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-57,960
Closed -$560K – 3042
2015
Q4 		$560K Buy
+57,960
New +$578K ﹤0.01% 2459
2014
Q3 		– Sell
-53,446
Closed -$742K – 2899
2014
Q2 		$742K Buy
+53,446
New +$712K ﹤0.01% 2189
2013
Q4 		– Sell
-136,711
Closed -$1.5M – 3074
2013
Q3 		$1.5M Buy
136,711
+55,422
+68% +$592K ﹤0.01% 1993
2013
Q2 		$657K Buy
+81,289
New +$547K ﹤0.01% 2233

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Frank Company's VNDA Position: Q1 2016 in Review

Russell Frank Company sold out of Vanda Pharmaceuticals (VNDA) in Q1 2016, closing a stake of 57,960 shares — an estimated $560K sold.

Russell Frank Company first reported a position in VNDA in Q2 2013 and held it in 4 quarters. The position peaked at $1.5M in Q3 2013. 116 funds tracked by Wall St. Rank hold VNDA as of Q1 2016.

  • Russell Frank Company reported no remaining Vanda Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Russell Frank Company sold 57,960 Vanda Pharmaceuticals shares in Q1 2016, an estimated $560K.
  • Russell Frank Company first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Russell Frank Company's Vanda Pharmaceuticals position peaked at $1.5M in Q3 2013.
  • 116 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.